WO2021207207A3 - De novo protein decoys of angiotensin-converting enzyme 2 (ace2) - Google Patents

De novo protein decoys of angiotensin-converting enzyme 2 (ace2) Download PDF

Info

Publication number
WO2021207207A3
WO2021207207A3 PCT/US2021/025974 US2021025974W WO2021207207A3 WO 2021207207 A3 WO2021207207 A3 WO 2021207207A3 US 2021025974 W US2021025974 W US 2021025974W WO 2021207207 A3 WO2021207207 A3 WO 2021207207A3
Authority
WO
WIPO (PCT)
Prior art keywords
ace2
angiotensin
converting enzyme
novo protein
decoys
Prior art date
Application number
PCT/US2021/025974
Other languages
French (fr)
Other versions
WO2021207207A2 (en
Inventor
Thomas Linsky
Daniel Adriano SILVA MANZANO
Nuria CODINA CASTILLO
Jorgen NELSON
Matthew James Walker
Original Assignee
Neoleukin Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neoleukin Therapeutics, Inc. filed Critical Neoleukin Therapeutics, Inc.
Priority to CA3173628A priority Critical patent/CA3173628A1/en
Priority to JP2022560982A priority patent/JP2023521706A/en
Priority to AU2021251760A priority patent/AU2021251760A1/en
Priority to CN202180029294.9A priority patent/CN115515972A/en
Priority to KR1020227036446A priority patent/KR20220164736A/en
Priority to EP21721753.8A priority patent/EP4132964A2/en
Publication of WO2021207207A2 publication Critical patent/WO2021207207A2/en
Publication of WO2021207207A3 publication Critical patent/WO2021207207A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein are de novo protein decoys of ACE2 and uses thereof. In some embodiments, methods of treating coronavirus infection using the ACE2 protein decoys are provided.
PCT/US2021/025974 2020-04-07 2021-04-06 De novo protein decoys of angiotensin-converting enzyme 2 (ace2) WO2021207207A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA3173628A CA3173628A1 (en) 2020-04-07 2021-04-06 De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
JP2022560982A JP2023521706A (en) 2020-04-07 2021-04-06 Angiotensin-converting enzyme 2 (ACE2) de novo protein decoy
AU2021251760A AU2021251760A1 (en) 2020-04-07 2021-04-06 De novo protein decoys of angiotensin-converting enzyme 2 (ACE2)
CN202180029294.9A CN115515972A (en) 2020-04-07 2021-04-06 De novo protein decoys for angiotensin converting enzyme 2 (ACE 2)
KR1020227036446A KR20220164736A (en) 2020-04-07 2021-04-06 De novo protein decoy of angiotensin converting enzyme 2 (ACE2)
EP21721753.8A EP4132964A2 (en) 2020-04-07 2021-04-06 De novo protein decoys of angiotensin-converting enzyme 2 (ace2)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202063006463P 2020-04-07 2020-04-07
US63/006,463 2020-04-07
US202063028401P 2020-05-21 2020-05-21
US63/028,401 2020-05-21
US202062705150P 2020-06-13 2020-06-13
US62/705,150 2020-06-13
US202063055051P 2020-07-22 2020-07-22
US63/055,051 2020-07-22
US202063060489P 2020-08-03 2020-08-03
US63/060,489 2020-08-03
US202063094179P 2020-10-20 2020-10-20
US63/094,179 2020-10-20
US202163145352P 2021-02-03 2021-02-03
US63/145,352 2021-02-03

Publications (2)

Publication Number Publication Date
WO2021207207A2 WO2021207207A2 (en) 2021-10-14
WO2021207207A3 true WO2021207207A3 (en) 2021-11-25

Family

ID=75675016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025974 WO2021207207A2 (en) 2020-04-07 2021-04-06 De novo protein decoys of angiotensin-converting enzyme 2 (ace2)

Country Status (7)

Country Link
EP (1) EP4132964A2 (en)
JP (1) JP2023521706A (en)
KR (1) KR20220164736A (en)
CN (1) CN115515972A (en)
AU (1) AU2021251760A1 (en)
CA (1) CA3173628A1 (en)
WO (1) WO2021207207A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032487A2 (en) * 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
WO2020018935A2 (en) * 2018-07-19 2020-01-23 University Of Washington De novo design of protein switches

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
JP2020508319A (en) 2017-02-24 2020-03-19 フィロジェン ソチエタ ペル アツィオーニ Immune complexes with optimized linkers and orientation
US10239862B2 (en) 2017-03-15 2019-03-26 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032487A2 (en) * 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
WO2020018935A2 (en) * 2018-07-19 2020-01-23 University Of Washington De novo design of protein switches

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANGHAI LEI ET AL: "Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig", 3 February 2020 (2020-02-03), XP055745522, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2.full.pdf> [retrieved on 20210629], DOI: 10.1101/2020.02.01.929976 *
EDOARDO MILANETTI ET AL: "In-Silico evidence for two receptors based strategy of SARS-CoV-2", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 24 March 2020 (2020-03-24), XP081636501 *
HOFMANN H ET AL: "Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 319, no. 4, 9 July 2004 (2004-07-09), pages 1216 - 1221, XP004515246, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.05.114 *
LINSKY THOMAS W ET AL: "De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), 5 November 2020 (2020-11-05), United States, pages 1208 - 1214, XP055833090, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/370/6521/1208.full-text.pdf> [retrieved on 20210819], DOI: 10.1126/science.abe0075 *
YANXIAO HAN ET AL: "Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2", ACS NANO, vol. 14, no. 4, 14 April 2020 (2020-04-14), US, pages 5143 - 5147, XP055732485, ISSN: 1936-0851, DOI: 10.1021/acsnano.0c02857 *

Also Published As

Publication number Publication date
WO2021207207A2 (en) 2021-10-14
JP2023521706A (en) 2023-05-25
AU2021251760A1 (en) 2022-10-06
CA3173628A1 (en) 2021-10-14
KR20220164736A (en) 2022-12-13
CN115515972A (en) 2022-12-23
EP4132964A2 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
EP2267121A3 (en) Lipolytic enzyme variants
PL387691A1 (en) Urate oxidase variants and their application
CA2275157A1 (en) A method for enzymatic treatment of biofilm
DE60231395D1 (en) DECELLULARIZATION OF TISSUE MATRIXES
ATE309373T1 (en) ALKALOPHILIC AND THERMOPHILIC MICROORGANISMS AND ENZYMES OBTAINED THEREFROM
WO2002060474A3 (en) Mixtures of mushroom enzymes and the use thereof for treating maldigestion
WO2005062832A3 (en) Enzyme expression methods
ATE466932T1 (en) REPRODUCTION OF VIRUSES IN CELL CULTURE
ATE473010T1 (en) ENZYMES FOR PHARMACEUTICAL USE
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
ATE450620T1 (en) STABLE CREATININE BIOSENSOR WITH THREE ENZYMES
WO2006137847A3 (en) Engineered enzymatically active bacteriophages and methods of uses thereof
WO2021174107A3 (en) Soluble ace2 variants and uses therefor
ES2142920T3 (en) PROCEDURE FOR OBTAINING A BIOMASS, USE OF THE BIOMASS RESULTING FROM THIS PROCEDURE AND FERMENT OF BAKING.
WO2021236957A3 (en) Ace2 muteins and methods of using the same
MX2023009756A (en) Amylase variants.
WO2006035445A3 (en) Methods of treating pathologies associated with oxidative stress
WO2002036078A3 (en) Targeting pluripotent stem cells to tissues
WO2021207207A3 (en) De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
AU2001282199A1 (en) A tyrosinase enzyme
ATE538206T1 (en) METHOD FOR BINDING ENZYME TO A SUPPORT USING CATIONIC COPOLYMERS AND PRODUCT PRODUCED THEREFROM
WO2003027265A3 (en) Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
ATE188203T1 (en) IMPROVED BIOLOGICAL DEGRADATION OF ORGANIC WASTE
WO2003104557A3 (en) Antibacterial packaging material including hop acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21721753

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3173628

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022560982

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021251760

Country of ref document: AU

Date of ref document: 20210406

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227036446

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021721753

Country of ref document: EP

Effective date: 20221107